Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:50 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 369 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Bone Mass Clear all

Conditions: Bone Mineral Density, Childhood Cancer Survivors
Interventions: Dual energy x-ray absorptiometry (DXA), Peripheral quantitative computed tomography (pQCT); Other
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 8 Years to 20 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Cushing Syndrome
Interventions: Not listed
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: Not listed
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1993 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Change in Bone Mineral Density, Bone Loss
Interventions: drospirenone 4 mg oral tablet or drospirenone 3.5 mg chewable tablet; Drug
Lead sponsor: Insud Pharma; Industry
Eligibility: 14 Years to 45 Years · Female only
Enrollment: 1,536 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2028
U.S. locations: 27
States / cities: Phoenix, Arizona • Aurora, Colorado • Boynton Beach, Florida + 17 more

Conditions: Uterine Cervical Neoplasms
Interventions: Zoledronic acid; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Osteoporosis, Osteopenia, Postmenopausal Osteoporosis
Interventions: Moringa Oleifera, Cabbage Placebo; Dietary Supplement
Lead sponsor: Appalachian State University; Other
Eligibility: 60 Years to 70 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Boone, North Carolina

Conditions: Osteoporosis
Interventions: phylloquinone (K1), menatetranone (MK4); Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: Female only
Enrollment: 375 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2004
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Osteoporosis
Interventions: Parathyroid hormone, Alendronate; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 46 Years to 85 Years · Male only
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2005
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Osteoporosis
Interventions: Placebo, Acetaminophen, Fluvastatin; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 45 Years to 79 Years · Female only
Enrollment: 793 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 1
States / cities: Http://www.osteoporosisclinicalresearch.com, New Jersey

Conditions: Contraception, Change in Bone Mineral Density
Interventions: Drospirenone; Drug
Lead sponsor: Insud Pharma; Industry
Eligibility: 13 Years to 45 Years · Female only
Enrollment: 1,542 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 46
States / cities: Alabaster, Alabama • Birmingham, Alabama • Tucson, Arizona + 36 more

Conditions: Osteoporosis
Interventions: denosumab, teriparatide; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 45 Years and older · Female only
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Anorexia Nervosa, Osteoporosis
Interventions: Placebo, Teriparatide; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 30 Years to 70 Years · Female only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cystic Fibrosis, Hypoestrogenism
Interventions: Transdermal estrogen, Progesterone; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 0 Years to 100 Years · Female only
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Postmenopausal Bone Loss
Interventions: Arzoxifene, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 45 Years to 60 Years · Female only
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: San Diego, California

Conditions: Osteopenia
Interventions: zoledronic acid; Drug
Lead sponsor: Novartis; Industry
Eligibility: 45 Years to 75 Years · Female only
Enrollment: 455 participants
Timeline: 2004 – 2005
U.S. locations: 6
States / cities: Unavailable, Georgia • Unavailable, Illinois • Unavailable, Indiana + 3 more

Conditions: Barrett's Esophagus, Erosive Esophagitis, Gastroesophageal Reflux Disease(GERD)
Interventions: Not listed
Lead sponsor: University of Pennsylvania; Other
Eligibility: 40 Years to 75 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Menopause, Fracture, Osteoporosis
Interventions: Teriparatide (PTH 1-34); Drug
Lead sponsor: Columbia University; Other
Eligibility: 20 Years to 48 Years · Female only
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 2
States / cities: Omaha, Nebraska • New York, New York

Conditions: Osteoporosis, Prostate Cancer
Interventions: dual x-ray absorptiometry; Procedure
Lead sponsor: University of Medicine and Dentistry of New Jersey; Other
Eligibility: 50 Years to 75 Years · Male only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Menopausal Osteoporosis
Interventions: VSL#3, Placebo; Drug · Other
Lead sponsor: Emory University; Other
Eligibility: 50 Years to 65 Years · Female only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Bone Mineral Density, Bone Strength
Interventions: LMHF mechanical stimulation active device, LMHF mechanical stimulation placebo device; Device
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 7 Years to 17 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Bone Diseases, Metabolic, Depression, Involutional, Osteoporosis
Interventions: Not listed
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: Not listed
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Neoplasms, Breast
Interventions: lapatinib, bevacizumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2020
U.S. locations: 9
States / cities: Tucson, Arizona • San Francisco, California • Hollywood, Florida + 6 more

Conditions: Vascular Calcification, Atherosclerosis, Bone Density
Interventions: CT of the bones; Procedure
Lead sponsor: University of Michigan; Other
Eligibility: 30 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Low Bone Density
Interventions: Teriparatide, Alendronate, calcium and vitamin D; Drug · Dietary Supplement
Lead sponsor: Johns Hopkins University; Other
Eligibility: 50 Years to 80 Years · Female only
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Juvenile Osteoporosis, Low Bone Density, Fractures
Interventions: Alendronate (Fosamax); Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 8 Years to 21 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Charleston, South Carolina

Search by objective public record fields.

Bone Mineral Density Status in Pediatric and Adolescent Survivors of Childhood Cancer With History of Bone Fracture

Long Term Post Operative Follow-Up of Cushing Syndrome

LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women

Study of Zoledronic Acid Versus Observation on Bone Mineral Density and Incidence of Micrometastasis in Women Undergoing Pelvic Radiation for Cervical Cancer

Moringa Oleifera on Bone Density

Vitamin K and Bone Turnover in Postmenopausal Women

Effects of Parathyroid Hormone in Men With Osteoporosis

Acetaminophen or Fluvastatin Compared to Placebo on the Transient Post-Dose Symptoms (PDS) Following an Intravenous (i.v.) Infusion of a Single Dose of Zoledronic Acid 5mg, in Post-menopausal Women With Low Bone Mass

Efficacy, Safety, and Tolerability of LPRI-CF113 as an Oral Contraceptive in Females

Denosumab, Teriparatide or Both for the Treatment of Postmenopausal Osteoporosis

The Role of Parathyroid Hormone (PTH) in Low Bone Mass in Anorexia Nervosa

Estrogen Supplementation and Bone Health in Women With CF

Effects of Arzoxifene on Bone Mass and the Uterus

To Assess the Efficacy of Over-the-counter Analgesics in the Prevention/Treatment of Transient Post-dose Symptoms Following Zoledronate Infusion in Post-menopausal Women

To Learn How Bone Structure and Bone Mass Change After Long-term PPI Use

Forteo for the Treatment of Unexplained Osteoporosis in Premenopausal Women

Bone Mineral Density and Cancer Recurrence in Patients With Early Stage Prostate Cancer

Effect of VSL#3 on Bone Mineral Density in Postmenopausal Women

Vibration Intervention For Bone Enhancement In Childhood Cancer Survivors

Use of Bone Biopsy to Better Understand the Causes of Decreased Bone Mineral Density in Depression

Lapatinib and Bevacizumab for Metastatic Breast Cancer

Association of Bone Quality and Quantity With Vascular Calcification

Stem Cell Recruitment in Osteoporosis Therapy

Alendronate in Juvenile Osteoporosis